Related Experiment Video
Updated: Jan 18, 2026

The Soft Agar Colony Formation Assay
Published on: October 27, 2014
NKX2-1 Restricts the Growth and Metastasis of Lung Squamous Cell Carcinoma Through Transcriptive Suppression of
Dan Yu1, Ping Liu1, Ruichen Gao1
1Department of Respiratory and Critical Care Medicine, The Third Affiliated Hospital of Nanjing Medical University, The Second People's Hospital of Changzhou, Changzhou, China.
Abstract:
Lung squamous cell carcinoma (LUSC) is associated with poor prognosis and limited treatment options. In this study, we investigate the role of NKX2-1 as a tumor suppressor in LUSC. Our analysis of The Cancer Genome Atlas (TCGA) revealed that NKX2-1 expression is significantly lower in LUSC tissues compared to lung adenocarcinoma (LUAD) and normal lung tissues, and patients with low NKX2-1 expression have poorer survival rates. The CCK8, colony formation, EdU incorporation, wound healing, and Transwell assays demonstrated that NKX2-1 overexpression inhibited the proliferation, migration, and invasion of the LUSC cell lines SK-MES-1 and NCI-H520. Moreover, in a subcutaneous xenograft model, NKX2-1 overexpression reduced tumorigenic potential of the injected SK-MES-1 cells. The transcriptomic analysis highlighted the dysregulation of key genes associated with NKX2-1 expression levels. AKR1B10 was expressed at higher levels in LUSC tissues and negatively correlated with NKX2-1. Dual-luciferase assays verified that NKX2-1 suppressed the transcription of AKR1B10 by direct binding to its promoter. The tumor-suppressive effects of NKX2-1 diminished upon AKR1B10 overexpression, which indicated an AKR1B10-dependent mechanism. In sum, our findings indicated that NKX2-1 limited tumor growth and metastasis in LUSC by repressing AKR1B10 transcription, thereby revealing potential therapeutic targets to improve clinical outcomes in these patients.
Insights
NKX2-1 acts as a tumor suppressor in lung squamous cell carcinoma (LUSC). Lower NKX2-1 levels correlate with poor survival, and its overexpression inhibits LUSC cell growth and metastasis by repressing AKR1B10.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Genetics
Background:
- Lung squamous cell carcinoma (LUSC) presents a significant clinical challenge due to poor prognosis and limited therapeutic strategies.
- The role of NKX2-1, a transcription factor, in LUSC pathogenesis remains incompletely understood.
- Identifying novel tumor suppressors and their mechanisms is crucial for developing effective LUSC treatments.
Purpose of the Study:
- To investigate the function of NKX2-1 as a potential tumor suppressor in LUSC.
- To elucidate the molecular mechanisms underlying NKX2-1's role in LUSC progression.
- To explore NKX2-1 and its downstream targets as potential therapeutic avenues for LUSC.
Main Methods:
- Analysis of The Cancer Genome Atlas (TCGA) data for NKX2-1 expression and correlation with patient survival.
- In vitro functional assays including CCK8, colony formation, EdU incorporation, wound healing, and Transwell assays to assess proliferation, migration, and invasion.
- In vivo studies using a subcutaneous xenograft model to evaluate tumorigenic potential.
- Transcriptomic analysis and dual-luciferase reporter assays to identify and validate NKX2-1 targets.
Main Results:
- NKX2-1 expression is significantly downregulated in LUSC tissues compared to lung adenocarcinoma (LUAD) and normal lung tissues, with lower expression linked to poorer survival.
- Overexpression of NKX2-1 suppressed proliferation, migration, and invasion in LUSC cell lines (SK-MES-1, NCI-H520) and reduced tumor growth in vivo.
- NKX2-1 directly suppresses AKR1B10 transcription, and this repression is critical for NKX2-1's tumor-suppressive effects in LUSC.
Conclusions:
- NKX2-1 functions as a tumor suppressor in LUSC by inhibiting cell proliferation, migration, and invasion.
- The tumor-suppressive activity of NKX2-1 is mediated, at least in part, through the repression of AKR1B10 transcription.
- Targeting the NKX2-1/AKR1B10 pathway may offer a novel therapeutic strategy for improving outcomes in LUSC patients.
More Related Videos
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
10:32Combined Use of Tail Vein Metastasis Assays and Real-Time In Vivo Imaging to Quantify Breast Cancer Metastatic Colonization and Burden in the Lungs
Published on: December 19, 2019
Related Concept Videos
Abnormal Proliferation
Mitogens and the Cell Cycle
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
The Ras Gene
Ras is a...
Epigenetic Regulation